Bracco Diagnostics Inc. Achieves 1 Million Injections with VUEWAY® (gadopiclenol) solution for injection
One Million Patients Led to This Moment
PRINCETON, N.J.—Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY® (gadopiclenol) solution for injection, has reached over one million patient injections at over 480 customer sites.1 This hallmark achievement is significant as it helped address the unmet medical need to minimize gadolinium (Gd) exposure per MRI procedure without compromising image quality.
VUEWAY® (gadopiclenol) solution for injection, 485.1 mg/mL is a macrocyclic gadolinium-based contrast agent (GBCA) that offers effective contrast enhancement at half the gadolinium (Gd) dose (0.05 mmol/kg) vs. a macrocyclic GBCA at a dose of 0.1 mmol/kg of other similar contrast media for approved indications in the U.S.2
Ryan Murtagh, MD, Chief of Neuroradiology at Tampa General Hospital and Tampa General Hospital Imaging, said, “As one of the first facilities to adopt VUEWAY (gadopiclenol) solution for injection back in February 2023, we are honored to have administered the one-millionth dose here at Tampa General. VUEWAY injection, with its FDA-labeled dose at half the gadolinium of what other approved macrocyclic agents require in similar indications, has proven to be a game-changer in our practice. It underscores our commitment to advancing patient care by embracing innovation."
With its lower dose of the active ingredient, Gd, VUEWAY injection is a desirable choice for all MRI patients especially those who may require multiple MRI scans with contrast throughout their care.
“We at Bracco are delighted with the rapid adoption of this exciting product (VUEWAY injection) and sincerely thank the imaging community for embracing this approach to patient care,” said Cosimo De Pinto, Senior Vice President of Sales and Marketing at Bracco Diagnostics Inc. “Our singular focus at Bracco is about improving patient lives and offering VUEWAY injection is a perfect example of this commitment. We’re proud to support our customers by providing the highest level of service, science, and breadth of innovative products,” concluded De Pinto.